Acadia Pharmaceuticals has announced a data breach affecting the medical information of over 3700 Texans. The breach was reported in a filing with the Attorney General of Texas on May 22, 2024. Details about the breach are limited, but it appears to be linked to the recently disclosed Cencora/Lash Group data breach. Notices are being sent to the affected individuals, informing them of the security incident.
The breach has raised questions about who will be responsible for notifying the affected parties and providing remedies. It remains unclear if the notices will come from Acadia Pharmaceuticals, Cencora/Lash Group, or both entities. The compromised data may include sensitive information such as names, dates of birth, addresses, and medical data, posing significant risks to the impacted individuals.
There is no current information on whether Acadia Pharmaceuticals will offer credit monitoring or identity theft protection services to those affected by the breach. However, Cencora/Lash Group has committed to providing 24 months of free credit monitoring and identity theft protection services to the affected individuals. This offer is part of their broader response to the security incident that has impacted multiple organizations.
Acadia Pharmaceuticals, a biopharmaceutical company based in San Diego, focuses on developing treatments for central nervous system disorders. Founded in 1993, the company aims to address unmet medical needs in neurological and psychiatric conditions. The data breach has brought attention to the importance of robust cybersecurity measures, especially for companies handling sensitive medical information.
Reference:
